Does the media prefer OGN or ELAN?

In the previous week, Organon & Co. had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 12 mentions for Organon & Co. and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.72 beat Organon & Co.'s score of 0.59 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OGN or AXSM?

In the previous week, Organon & Co. and Organon & Co. both had 12 articles in the media. Axsome Therapeutics' average media sentiment score of 0.77 beat Organon & Co.'s score of 0.59 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or OGN?

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Organon & Co.. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 12 mentions for Organon & Co.. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Organon & Co.'s score of 0.59 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ABVX or OGN?

Organon & Co. has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Organon & Co. $6.22B 0.57 $187M $0.93 14.58

Is ABVX or OGN more profitable?

Organon & Co. has a net margin of 3.41% compared to Abivax's net margin of 0.00%. Organon & Co.'s return on equity of 92.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Organon & Co. 3.41% 92.94% 6.04%

Does the media prefer ABVX or OGN?

In the previous week, Abivax had 2 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Abivax and 12 mentions for Organon & Co.. Abivax's average media sentiment score of 1.41 beat Organon & Co.'s score of 0.59 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OGN or SMMT?

In the previous week, Summit Therapeutics had 2 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Summit Therapeutics and 12 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.59 beat Summit Therapeutics' score of 0.35 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Organon & Co. (OGN) Competitors

$13.56 +0.01 (+0.04%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$13.55 0.00 (-0.04%)

As of 07/31/2026 07:34 PM Eastern

Compare

OGN vs. ELAN, AXSM, ARWR, ABVX, and SMMT

Should you buy Organon & Co. stock or one of its competitors? MarketBeat compares Organon & Co. with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organon & Co. include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Summit Therapeutics (SMMT).

How does Organon & Co. compare to Elanco Animal Health?

Organon & Co. (NYSE:OGN) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 15.90%. Elanco Animal Health has a consensus price target of $28.73, suggesting a potential upside of 8.72%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Organon & Co. had 3 more articles in the media than Elanco Animal Health. MarketBeat recorded 12 mentions for Organon & Co. and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.72 beat Organon & Co.'s score of 0.59 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.58
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A

Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Organon & Co. has a net margin of 3.41% compared to Elanco Animal Health's net margin of -4.95%. Organon & Co.'s return on equity of 92.94% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	92.94%	6.04%
Elanco Animal Health	-4.95%	7.42%	3.66%

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Organon & Co. beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Organon & Co. (NYSE:OGN) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Organon & Co. has a net margin of 3.41% compared to Axsome Therapeutics' net margin of -26.59%. Organon & Co.'s return on equity of 92.94% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	92.94%	6.04%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Organon & Co. and Organon & Co. both had 12 articles in the media. Axsome Therapeutics' average media sentiment score of 0.77 beat Organon & Co.'s score of 0.59 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 15.90%. Axsome Therapeutics has a consensus price target of $261.29, indicating a potential upside of 19.86%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.58
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Summary

Organon & Co. and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Organon & Co.'s return on equity of 92.94% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Organon & Co.	3.41%	92.94%	6.04%

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Organon & Co.. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 12 mentions for Organon & Co.. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Organon & Co.'s score of 0.59 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.38	-$1.63M	-$2.15	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.58

Arrowhead Pharmaceuticals presently has a consensus target price of $96.92, indicating a potential upside of 14.49%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 15.90%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Organon & Co. beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Abivax?

Abivax (NASDAQ:ABVX) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Organon & Co. has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.58

Abivax has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Abivax currently has a consensus target price of $156.50, suggesting a potential upside of 25.28%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 15.90%. Given Abivax's stronger consensus rating and higher possible upside, equities research analysts plainly believe Abivax is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Abivax had 2 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Abivax and 12 mentions for Organon & Co.. Abivax's average media sentiment score of 1.41 beat Organon & Co.'s score of 0.59 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a net margin of 3.41% compared to Abivax's net margin of 0.00%. Organon & Co.'s return on equity of 92.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Organon & Co.	3.41%	92.94%	6.04%

Summary

Organon & Co. beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Organon & Co. compare to Summit Therapeutics?

Organon & Co. (NYSE:OGN) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

In the previous week, Summit Therapeutics had 2 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for Summit Therapeutics and 12 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.59 beat Summit Therapeutics' score of 0.35 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 15.90%. Summit Therapeutics has a consensus target price of $26.15, suggesting a potential upside of 100.88%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Organon & Co. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.58
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Organon & Co. has a net margin of 3.41% compared to Summit Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 92.94% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	92.94%	6.04%
Summit Therapeutics	N/A	-168.94%	-141.92%

Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Organon & Co. beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.56B	$11.71B	$6.86B	$23.67B
Dividend Yield	0.59%	2.72%	2.59%	4.22%
P/E Ratio	17.60	799.05	282.27	31.00
Price / Sales	0.57	752.05	563.88	19.22
Price / Cash	2.34	14.82	28.60	18.73
Price / Book	4.69	10.39	10.93	4.76
Net Income	$187M	$2.82B	$3.49B	$1.07B
7 Day Performance	0.22%	-0.11%	-0.61%	-0.34%
1 Month Performance	-0.07%	-3.96%	-3.75%	-0.53%
1 Year Performance	38.88%	156.19%	62.10%	19.19%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	2.0599 of 5 stars	$13.56 +0.0%	$11.40 -15.9%	+38.9%	$3.56B	$6.22B	17.60	10,000	Trending News Dividend Announcement
ELAN Elanco Animal Health	2.9342 of 5 stars	$25.48 +2.3%	$28.73 +12.7%	+91.5%	$12.44B	$4.72B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
AXSM Axsome Therapeutics	3.3063 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+111.6%	$12.40B	$638.50M	N/A	380	Upcoming Earnings Analyst Forecast Gap Up
ARWR Arrowhead Pharmaceuticals	2.33 of 5 stars	$85.53 -0.1%	$95.08 +11.2%	+431.4%	$12.06B	$829.45M	N/A	400	Upcoming Earnings
ABVX Abivax	3.9263 of 5 stars	$128.00 +1.8%	$156.50 +22.3%	+73.6%	$10.97B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. ELAN, AXSM, ARWR, ABVX, and SMMT

How does Organon & Co. compare to Elanco Animal Health?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Summary

How does Organon & Co. compare to Arrowhead Pharmaceuticals?

Summary

How does Organon & Co. compare to Abivax?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. ELAN, AXSM, ARWR, ABVX, and SMMT

How does Organon & Co. compare to Elanco Animal Health?

Do analysts recommend OGN or ELAN?

Does the media prefer OGN or ELAN?

Which has higher valuation & earnings, OGN or ELAN?

Which has more volatility and risk, OGN or ELAN?

Is OGN or ELAN more profitable?

Do institutionals & insiders have more ownership in OGN or ELAN?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Is OGN or AXSM more profitable?

Does the media prefer OGN or AXSM?

Do analysts recommend OGN or AXSM?

Which has higher earnings and valuation, OGN or AXSM?

Do institutionals & insiders believe in OGN or AXSM?

Which has more risk and volatility, OGN or AXSM?

Summary

How does Organon & Co. compare to Arrowhead Pharmaceuticals?

Do institutionals and insiders hold more shares of ARWR or OGN?

Is ARWR or OGN more profitable?

Does the media favor ARWR or OGN?

Which has better earnings & valuation, ARWR or OGN?

Do analysts rate ARWR or OGN?

Which has more risk and volatility, ARWR or OGN?

Summary

How does Organon & Co. compare to Abivax?

Which has stronger earnings & valuation, ABVX or OGN?

Which has more risk & volatility, ABVX or OGN?

Do insiders & institutionals hold more shares of ABVX or OGN?

Do analysts recommend ABVX or OGN?

Does the media prefer ABVX or OGN?

Is ABVX or OGN more profitable?

Summary

How does Organon & Co. compare to Summit Therapeutics?

Does the media favor OGN or SMMT?

Do analysts recommend OGN or SMMT?

Which has preferable earnings and valuation, OGN or SMMT?

Is OGN or SMMT more profitable?

Which has more risk & volatility, OGN or SMMT?

Do institutionals & insiders hold more shares of OGN or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools